A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 570 participants.
Also called NCT05002933
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 570 participants
- Sponsor
- Registry
-
NCT05002933 -
U1111-1251-4484
-
- Other papers using this trial's data
- Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05002933. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-20 (actual); primary completion 2023-02-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
- Acronym
- INITIATION
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine 300 U/ml
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct05002933- Content hash
40a0ec79aab162c508eaacc839aa7bc2a5529d964685d11ab985488d56d8511a